

Figure 1

Changes in sUA in human subjects having (a) normal and stage 1 CKD, (b) stage 2 CKD, and (c) stage 3 CKD after treatment with (-)-halofenate at 600 mg per day




Figure 2

Changes in sUA in human subjects having stage 2
and 3 CKD after treatment with (-)-halofenate




Figure 3

Changes in serum uric acid level in human subjects having stage 3, stage 2 and stage 1 CKD after treatment with (-)-halofenate




Figure 4

Changes creatinine clearance in human subjects
after treatment with (-)-halofenate




Figure 5

Changes in HbA1c levels in human subjects having stage 2 and stage 3 CKD after treatment with (-)-halofenate




Figure 6

Changes in FPG levels in human subjects having stage 2 and stage 3 CKD after treatment with (-)-thalofenate

5




Figure 7

Changes in TG levels in human subjects having stage 2 and stage 3 CKD after treatment with (-)-thalofenate




Figure 8

Changes in serum uric acid levels in human subjects on aspirin therapy




Figure 9

Changes in serum uric acid levels in human subjects on diuretic therapy

